BRAF alterations represent a novel indicator of the progression and aggressiveness of thyroid carcinogenesis. So, the main aim of the study was to elucidate the involvement of BRAF gene mutations and its expression in Kashmiri (North India) patients and investigate their association with clinico-pathological characteristics. Mutational analysis of BRAF gene was performed by polymerase chain reaction followed by DNA sequencing, whereas analysis of BRAF protein expression was done by western blotting. Overall mutations in BRAF was found to be 25% (15 of 60) and all of them were transversions (T>A) affecting codon 600 (valine to glutamine), restricted only to papillary thyroid cancer and well-differentiated grade. Patients with welldifferentiated disease and in particular elevated thyroidstimulating hormone levels were significantly associated with BRAF mutations (P < 0.05). Overall, 90% (54 of 60) of thyroid cancer cases showed increased expression of BRAF and non-smokers being significantly associated with BRAF over-expression. Totally, 86.7% (13 of 15) of BRAF mutation-positive patients were having over-expression of BRAF protein, whereas 91.2% (41 of 45) of patients with wild-type BRAF status were having over-expressed BRAF protein (P > 0.05). We conclude that both mutational events as well as over-expression of BRAF gene is highly implicated in pathogenesis of thyroid cancer and the BRAF protein overexpression is independent of the BRAF mutational status of thyroid cancer patients.
Introduction
Thyroid cancer is the most common malignancy of the endocrine system. It accounts for ~2% of all newly diagnosed cancer cases and majority of endocrine cancer-related deaths each year (1) (2) (3) . Its prevalence continues to rise; in 2008, it became the sixth most diagnosed cancer in women. The most recent and major development in the field of thyroid cancer genetics has been the identification of the BRAF-activating point mutation as the most common molecular defect in papillary thyroid cancer (PTC) (4) . The BRAF-activating point mutation in thyroid cancer is almost exclusively a thymine-toadenine transversion at position 1799 (T1799A) in exon 15 .
This leads to a valine-to-glutamate substitution at residue 600 (V600E) and subsequent constitutive activation of the BRAF kinase (5, 6) . Recent studies have reported a prevalence of BRAF mutation in 29-83% of PTC, making it the most common oncogene identified in sporadic forms of PTC (4, 7) . In all the studies published to date, BRAF mutation (V600E) has been found only in PTC, poorly differentiated thyroid cancer and anaplastic thyroid cancer (4) . PTCs with BRAF mutation have distinct phenotypic and biologic properties. They seem to behave more aggressively and carry a poorer prognosis (8) . Distinct alterations in gene expression have been observed in papillary carcinomas and other types of thyroid cancer (9, 10) . Previous studies have shown that rate of BRAF protein expression in PTC was significantly higher than that in multinodular goiter (MNG) . Similarly, among the PTC tissues, the positive rate was significantly higher in the lymph node metastasis (LNM) group than in the non-LNM group. Gene copy number gain may reflect one of the major mechanisms causing over-expression of the BRAF protein (11, 12) .
Keeping in view the pivotal role played by BRAF alterations in thyroid carcinogenesis, the present study was aimed at analysing the BRAF mutational spectrum and its protein expression in thyroid cancer and paired normal tissues and evaluation of its various clinico-pathological characteristics.
Materials and methods

Patients and controls
A total of 60 histologically confirmed, previously untreated thyroid cancer patients attending Department of General Surgery at Sher-I-Kashmir Institute of Medical Sciences (SKIMS), Srinagar, were included in this study. Tumour tissue was available for all 60 patients along with corresponding normal tissue samples. A written pre-informed consent was obtained from all cases and controls. A 'pre-informed consent form' was used to collect demographic and clinico-pathological characteristics of each patient. This study was approved by the Ethical Committee of the SKIMS.
Sample collection/storage
The surgically resected tissue samples by total thyroidectomy, hemi-thyroidectomy or lobectomy were collected directly into sterile vials containing chilled phosphate-buffered saline (PBS, pH = 7.2) and frozen at −70°C for molecular investigations. Adjacent normal tissues were also resected from the thyroid gland.
Polymerase chain reaction for amplification of BRAF gene DNA was extracted from the tumour and adjacent normal tissues by using DNA Extraction kit (Zymo Research Corporation, Irvine, CA, USA). To amplify BRAF gene exon 15, we used genomic DNA: 250 ng/µl; 10× polymerase chain reaction buffer: 100 mM Tris-HCl (pH 8.3); 500 mM KCl; 15 mM MgCl 2 ; 0.1% gelatine; 1% Triton X100; deoxyribonucleotide triphosphate: 10 mM each dATP, dCTP, dGTP and dTTP (Cinnagen Co., Tehran, Iran); primers: 10 pM in sterile deionised water (Sigma-Aldrich, St Louis, MO, USA) and Taq DNA polymerase: 5 U/µl (Biotools, Madrid, Spain). The set of primers used to amplify exon 15 of BRAF were as follows: forward (5′-TCATAATGCTTGCTCTGATAGGA-3′) and reverse (5′-GGCCAAAAATTTAATCAGTGGA-3′). After an initial denaturation at 95°C for 7 min, 35 cycles of 94°C for 35 s, a specific annealing temperature (58°C) for 35 s, and 72°C for 35 s were performed with a final elongation at 72°C for 7 min. The amplified products were detected and confirmed by comparing with a 100-bp DNA marker ladder by electrophoresis on 2% agarose gel containing ethidium bromide (0.5 µg/ml) in a mini-gel system (Scie-Plas Ltd, Cambridge, UK) and visualised in UV illuminator (Fluorchem HD2; Cell Bioscience Inc., Santa Clara, CA, USA). DNA sequencing was carried out by automated DNA sequencing method on ABI Prism 310 (Perkin Elmer, Waltham, MA, USA). A confirmed DNA sample, which was previously checked for amplification, was used as a positive control and water was used as a negative control.
Western blotting for expression of BRAF protein
Equal amounts of protein (50 µg) were solubilised in sample buffer [0.5 mol/l Tris-HCl (pH, 6.8); 1.25% sodium dodecyl sulphate (SDS); 10% glycerol; 2.5% β-mercaptoethanol and 0.03% bromophenol blue], boiled at 100°C for 5 min and then spinned down for 1 min. Samples were separated on SDS-10% polyacrylamide gel and transferred electrophoretically to polyvinylidene difluoride membrane. Membranes were blocked in 5% non-fat dried milk for 90 min at room temperature with gentle agitation on shaker and then probed with the appropriate primary antibodies at 4°C overnight. Primary antibodies and working dilution rates were as follows: BRAF mAb, 1:500 (A-00774; GenScript USA Inc.) and β-actin, 1:1000 (ab-3280; Abcam, Hong Kong). Membranes were washed three times for 10 min and 5 min each in PBS containing 0.5% Tween-20 and incubated with horseradish peroxidase-conjugated anti-mouse antibody (1:10 000; Alexaflor LI-COR) for 2 h at room temperature. After washing the membranes, targeted proteins were visualised using the enhanced chemiluminescence detection system (Odyssey Imaging Systems, LI-COR Biosciences, USA).
Statistical analysis
Statistical analysis was performed by using SPSS software (V.16.0). Chisquare test for homogeneity of proportions was used to determine significance of mutation pattern and odds ratio was used to determine association of presence of mutations with various clinico-epidemiological characteristics such as age, site of tumour, clinical tumour stage and histopathological grade of tumour. Statistical significance was considered when P ≤0.05.
Results
A total of 60 consecutive thyroid tumours and their adjacent normal tissues surgically resected between the years 2010 and 2012 were included in this study for sequence analysis of BRAF gene. All the samples resected were established as thyroid cancer through histopathological analysis. Majority of the patients had attended the hospital with a clinical presentation of a lump or nodule, a hallmark of thyroid cancer. In this study, 20% (12 of 60) of the cases were males and 80% (48 of 60) were females with a male:female ratio of 1:4. The clinico-pathological characteristics of these patients are listed in Table I .
Mutational spectrum of BRAF gene
Overall mutations in exon 15 of BRAF identified in this study aggregated to 25% (15 of 60). In all, there were 15 missense mutations and all of them were transversions (T>A) (Figure 1 ). We detected a single type of nucleotide substitution in 15 of the 60 thyroid carcinomas, which is a hot spot for BRAF gene (Tables II and III) . This mutation affects codon 600 of BRAF gene. The matched constitutional DNA contained the wild-type sequence in every case, demonstrating the somatic nature of these mutations in thyroid cancer.
Among 25% (15 of 60) mutations of BRAF gene found, 40% (10 of 25) of cases having elevated thyroid-stimulating hormone (TSH) levels were harbouring mutation compared to 14.2% (5 of 35) cases having normal TSH levels and this difference showed a statistical significance (P < 0.05) (Table II) . Among the various histological types of thyroid cancer, mutations were restricted only to PTC. So, 35.7% (15 of 42) of PTC patients were having mutation in codon 600 of BRAF gene compared to patients with follicular and other types of thyroid cancer, who did not have any mutation, and this difference in mutation frequency between different histological types of tumours was statistically significant (P < 0.05). All the mutations were found in well-differentiated thyroid carcinomas (26.3%, 15 of 57) as compared to poorly differentiated thyroid carcinomas (P < 0.05). In thyroid cancer patients having <45 years of age, 23.5% (8 of 34) of patients with Stage I disease had mutation compared to 100% (2 of 2) in Stage II patients. Similarly, 33.3% (5 of 15) of thyroid cancer patients, ≥45 years of age, with Stage I disease had mutation, whereas Stage II patients were found to be free from mutation (P < 0.05) ( Table II) .
Analysis of BRAF protein expression
In the present study, 60 thyroid cancer tissues and their adjacent normal samples previously studied for mutation spectrum were analysed for the BRAF protein expression. The clinicoepidemiological and clinico-pathological characteristics of the studied subjects are given in Table I .
Out of 60 cases of thyroid cancer, 90% (54 of 60) showed over-expression of BRAF protein (Figure 2 ) and the rest 10% (6 of 60) of the cases showed normal protein (BRAF) expression. Over-expression of BRAF protein in males was observed to be 84% (10 of 12) and in females as 91.6% (44 of 48). Among nonsmokers, 96.3% (52 of 54) showed over-expression compared to smokers who showed only 33.4% (2 of 6) over-expression in BRAF protein and the difference is statistically significant (P > 0.05). BRAF protein over-expression was found in 97.7% (41 of 42) of PTC, 75% (6 of 8) of Follicular Thyroid Cancer and 70% (7 of 10) of medullary/Hurthle cell carcinomas with a statistically significant association (P > 0.05) (Table IV) .
When we compared BRAF gene mutational status with BRAF protein expression, 86.7% (13 of 15) of BRAF mutation-positive patients were having over-expression of BRAF protein, whereas 91.2% (41 of 45) of patients with wildtype BRAF status were having over-expressed BRAF protein (P > 0.05) (Table V) . So, the BRAF protein over-expression was independent of the BRAF mutational status of thyroid cancer patients. 
Discussion
The mitogen-activated protein kinase (MAPK) pathway is an ancient and conserved signalling pathway and regulates diverse processes ranging from proliferation and differentiation to apoptosis. BRAF mutations have recently been identified as the most common genetic event in papillary thyroid carcinomas (13) . All three functional human RAF proteins-A-RAF, B-RAF and C-RAF (or c-Raf-1)-share several highly conserved regions in the N-terminal regulatory domain and C-terminal kinase domain. RAF activation is triggered by RAS binding and protein recruitment to the cell membrane, which ultimately stimulates its serine/threonine kinase activity. RAF phosphorylates and activates MEK, which in turn activates ERK and consequent effectors of the MAPK cascade. Of all RAF proteins, BRAF has the highest basal kinase activity and is more active in phosphorylating MEK upon RAS activation than the other two family members (14) . BRAF gene alterations has been observed to be implicated in pathogenesis of various cancers like malignant melanoma (27-70%), colorectal cancer (5-22%), and serous ovarian cancer (<30%) including thyroid cancer (40-45%) (6) . BRAF mutation and over-expression represents a novel indicator of the progression and aggressiveness in the carcinogenesis of thyroid tissue.
In this study, the only mutation found (25%, 15 of 60) involves a thymine-to-adenine substitution at nucleotide position 1799, which results in a valine-to-glutamate replacement at residue 600 (V600E). BRAF V600E mutation constitutes 98-99% of all BRAF mutations found in thyroid cancer, which occurs in the activation loop of the kinase (7, 8) . The substitution of the negatively charged glutamic acid for an uncharged valine at position 600 may mimic the normal physiological phosphorylation of T599 and S602, resulting in a constitutively activated BRAF kinase stimulating BRAF activity up to 700-fold (15) .
The BRAF mutation was restricted to PTC. Overall, 35.7% of PTC patients were found positive for BRAF mutation, which is in accordance with several previous studies (35-69% versus 35.7%, our study) (4, 7, 8, 16, 17) . The BRAF K600E mutation was reported in follicular variants of PTC by few studies (18, 19) , but this type of mutation was not found in our population.
No study has reported to have observed any association between BRAF mutational status and TSH levels in the etiopathogenesis of thyroid cancer (20) (21) (22) (23) . Boelaert et al. found increased odds of malignancy in those patients with solitary nodules and elevated TSH levels (24) . Interestingly, our investigation found a positive association between TSH levels and BRAF mutation. In the analysis done by Megan et al., TSH was an independent predictor of Differentiated Thyroid Cancer on univariate and multivariable analysis (25) . The TSH level in high-risk patients, such as those with Stage III or IV disease, may be targeted at the undetectable level regardless of the BRAF mutation status as conventionally recommended until further studies become available (26) . Interestingly, in thyrocytes, TSH strongly activates cyclic AMP and promotes thyrocyte cell proliferation (27, 28) . Therefore, it is likely that mutation of BRAF in thyrocytes may be related to cyclic AMP, although how exactly cyclic AMP results in BRAF gene mutation remains elusive. All the BRAF mutation-positive thyroid tumour samples in our study were having well-differentiated cancer grade, which is somewhat in agreement with several studies that have reported similar incidence of BRAF V600E mutations in undifferentiated and well-differentiated early-stage tumours of thyroid (29, 30) . Though pattern of mutations were associated with advanced stage thyroid tumours in patients <45 years of age, it is inappropriate to draw any conclusion as the frequency of patients with advanced disease is less as compared to early thyroid disease. We found a significantly higher number of mutations in higher stages of thyroid tumours in patients of age <45 years (P < 0.05), which is in agreement with many studies (31) (32) (33) .
In patients of ≥45 years of age, BRAF mutations were associated with lower stages (P < 0.05), which is in contrast with majority of studies (29-31) but in coherence with few studies (34) (35) (36) . This discrepancy in the pattern of BRAF mutation in different age groups shows its involvement through the early to late stages. In accordance with many studies, we found association between BRAF V600E mutation and LNM (37) (38) (39) (40) .
We found over-expression of BRAF in 90% (54 of 60) of thyroid cancer cases, which is in accordance with few studies (11, 41, 42) . BRAF protein over-expression was further observed to be associated with non-smokers (P < 0.05). Compared to other histological types of thyroid cancer, BRAF protein was found to be over-expressed in papillary (97.7%) and follicular (75%) histotypes and the association was significant. This finding is in accordance with a study done by Kondo et al. who reported over-expression of BRAF in papillary (94%, 29 of 31 cases) as well as follicular thyroid carcinomas (94%, 15 of 16 cases) (11) , but in contrast with study done by Ciampi et al. who found BRAF protein over-expression associated with follicular thyroid cancer of conventional and oncocytic type (16 and 45%) as compared to PTC (3%) (42) . Another study has reported significantly higher rate of BRAF protein expression in PTC than that in MNGs (43) .
A distinct association between BRAF expression and mutation in thyroid tumours in our series could not be identified as previously reported (11, 43) . The independent pattern of either events in BRAF mutation or expression was observed, which might possibly be due to some another potential mechanism of BRAF activation other than mutational events. BRAF copy number gain in thyroid tumours may be one factor that has recently been studied by fluorescence in situ hybridisation, where trisomy/tetrasomy for chromosome 7 was the most common alteration in tumours (42) . Thus, our data suggest that BRAF gene may represent an important target for the selection and clonal progression. Furthermore, a unifying feature of the V600E BRAF mutation is that it disrupts the glycine-rich loop/activation segment interaction, destabilising the inactive conformation and stimulating BRAF activity up to 700-fold (6) . The numerical changes of BRAF involving gains of one to three extra copies of the gene would be expected to result in the modest over-expression of the protein. Indeed, as revealed by western blotting experiments, the amount of BRAF protein is approximately doubled in tumours harbouring four copies of the gene. This is likely to lead to some additional stimulation of the MAPK pathway, although the level of stimulation would be significantly lower compared to those imposed by V600E point mutation (11, 42) . Therefore, it is tempting to speculate that weak stimulation of the MAPK pathway may participate in thyroid carcinogenesis.
Conclusion
In conclusion, our study shows that the BRAF mutations as well its protein over-expression characterises the predominant pathway of thyroid tumorigenesis and both events are independent of each other. Association of BRAF derangement with elevated TSH level and in non-smokers has been the interesting outcomes of the study. Detection of this mutation from fine needle aspiration cytology samples of patients having thyroid tumours may represent a valid adjunctive tool for screening, surgical intervention and management of thyroid cancer patients.
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